NEW YORK (GenomeWeb News) – Molecular diagnostics firm AutoGenomics lowered the net proceeds it expects from a planned initial public offering to $53.7 million, it said in an amended Form S-1 filed with the US Securities and Exchange Commission on Wednesday.

In the filing, the company said that it plans to offer 6 million shares of its common stock at a price of between $9 and $11 per share. It plans to list its shares on the Nasdaq under ticker symbol "AGMX".

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.